What's in Jeil Pharmaceutical Co., Ltd.'s pipeline?

Jeil Pharmaceutical Co., Ltd. has 25 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 3 in Phase 2, 15 in Phase 1.

Which companies overlap with Jeil Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Boryung Pharmaceutical Co., Ltd, National Heart, Lung, and Blood Institute (NHLBI), AJU Pharm Co., Ltd., Abbott, AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/jeil-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Jeil Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Jeil Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 3 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
"Metformin" and "Rosuvastatin" seperately	"Metformin" and "Rosuvastatin" seperately	marketed
Clopirin 1	Clopirin 1	marketed
Clopirin 2	Clopirin 2	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor	Cardiovascular
Metformin + Rosuvastatin	Metformin + Rosuvastatin	phase 3	Antidiabetic agent + HMG-CoA reductase inhibitor (statin)	Metformin: AMP-activated protein kinase (AMPK) pathway; Rosuvastatin: HMG-CoA reductase	Endocrinology / Cardiovascular
placebo + Rosuvastatin	placebo + Rosuvastatin	phase 3	HMG-CoA reductase inhibitor	HMG-CoA reductase	Cardiovascular
JLP-2002 A mg	JLP-2002 A mg	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
JT-003	JT-003	phase 3

Therapeutic area mix

Cardiovascular · 2
Diabetes · 1
Endocrinology / Cardiovascular · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
National Heart, Lung, and Blood Institute (NHLBI) · 2 shared drug classes
AJU Pharm Co., Ltd. · 1 shared drug class
Abbott · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
Aciex Therapeutics, Inc. · 1 shared drug class
AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jeil Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jeil Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jeil-pharmaceutical-co-ltd. Accessed 2026-05-16.